These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 29397408)

  • 1. Bisphosphonate use after clinical fracture and risk of new fracture.
    Bergman J; Nordström A; Nordström P
    Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and mortality: confounding in observational studies?
    Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
    Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
    Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
    N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
    Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
    Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
    Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
    J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of second hip fracture and compliant use of bisphosphonate.
    Lee YK; Ha YC; Yoon BH; Koo KH
    Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?
    Ha KY; Park KS; Kim SI; Kim YH
    Osteoporos Int; 2016 Feb; 27(2):483-8. PubMed ID: 26202489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for older men with fractures.
    Shepherd AJ; Cass AR; Ray LA; Tan A; Wilkinson GS
    Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
    Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
    J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults.
    Zullo AR; Sorial MN; Lee Y; Lary CW; Kiel DP; Berry SD
    J Am Geriatr Soc; 2020 Feb; 68(2):256-260. PubMed ID: 31580488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.